anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
400,980. Removing superfluous hair. FRANCIS, E. L., 88, Chancery Lane, London.-(Halwit Laboratorium Ges. ; 21, Waldhornstrasse, Karlsruhe, Baden, Germany.) April 29, 1932, No. 12424. [A Specification was laid open to inspection under Sect. 91 of the Acts, April 30, 1932]. [Class 131.] A depilatory composition which lathers with water comprises an alkaline earth sulphide which acts as a depilatory, albumen, an albuminate, a caseinate or a mixture of a protalbinate and a lysalbinate, which acts as a lathering agent, and a sulphocyanide or a soluble iodide, bromide or nitrate, which accelerates the action of the composition. In an example, the composition comprises 42 per cent strontium sulphide, 17 per cent chalk, 20 per cent starch, 10 per cent albumen, 10 per cent potassium sulphocyanide and 1 per cent perfume. A mixture containing a protalbinate, a lysalbinate and a sulphocyanide for use in the composition may be obtained by decomposing albumen by heating with alkali, adding sulphuric acid to neutralize a substantial part of the alkali, adding barium sulphocyanide, and then drying the resulting product by spraying through an atomizing dryer at a temperature of 55-60‹ C.
A method of reducing respiratory alkalosis (high blood pH) and enhancing productivity (rate of weight gain) in poultry during periods of chronic or acute heat stress (high heat and humidity) involving the steps of supplementing the birds' diet (feedstuffs and/or water) with acids (hydrogen ion donor) and bicarbonate donors (NaHCO 3 ) or supplementing the birds' drinking water with additional potassium ion (e.g. KCl or K 2  CO 3 ) and/or ammonium chloride with or without NaHCO 3  and ascorbic acid. The addition of an acid donor as a poultry feed or water additive and the use of additional potassium in the drinking water significantly reduces the alkalosis induced mortality rate and enhances the rate of weight gain (up to 30 percent). By including NaHCO 3  in the feed ration, the rate of gain is further enhanced (an additional 9 percent). The further intention addition of a sodium free, chloride ion donor also promotes increased rate of gain. The use of a H 2  antagonist (cimetidine) to reduce stomach acid production is also beneficial to increase growth rate and mortality by reducing blood pH.
Aims: Hypopharyngeal cancer (HPC) is associated with the worst prognosis of all head and neck cancers and is typically identified in an advanced stage at the time of diagnosis. While oxidative stress might contribute to the onset of HPC in patients using tobacco or alcohol, the extent of this influence and the characteristics of HPC cells in advanced stage remain to be investigated. In this study, we explored whether HPC cells survived from necrotic xenograft tumors at late stage would display increased tumor resistance along with altered tolerance to oxidative stress. Results: The remnant living HPC cells isolated from a late-stage xenograft tumor, named FaDu ex vivo cells, showed stronger chemo- and radioresistance, tumorigenesis, and invasiveness compared with parental FaDu cells. FaDu ex vivo cells also displayed increased angiogenic ability after re-transplantation in mice visualized by in vivo near infrared-II fluorescence imaging modality. Moreover, FaDu ex vivo cells exhibited significant tumor-initiating cell (TIC)-related properties accompanied by a reduction of the level of reactive oxygen species, which was associated with the upregulation of transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Interestingly, inhibition of Nrf2 by the RNA interference and the chemical inhibitor could reduce the TIC-related properties of FaDu ex vivo cells. Innovation: Oxidative stress potentially initiates HPC, but elevation of Nrf2-associated antioxidant mechanisms would be essential to mitigate this effect for promoting and sustaining the stemness of HPC at the advanced stage. Conclusion: Present data suggest that the antioxidant potency of advanced HPC would be a therapeutic target for the design of adjuvant treatment. Antioxid. Redox Signal. 41, 505-521.
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
Hemodialysis is a conservative treatment for end-stage renal disease. It has various complications which negatively affect quality of life (QOL). This study aimed to examine the relationship between fatigue, pruritus, and thirst distress (TD) with QOL of patients receiving hemodialysis, while also considering the mediating role of treatment adherence (TA). This cross-sectional study was carried out in 2023 on 411 patients receiving hemodialysis. Participants were consecutively recruited from several dialysis centers in Iran. Data were collected using a demographic information form, the Fatigue Assessment Scale, the Thirst Distress Scale, the Pruritus Severity Scale, the 12-Item Short Form Health Survey, and the modified version of the Greek Simplified Medication Adherence Questionnaire for Hemodialysis Patients. Covariance-based structural equation modeling was used for data analysis. The structural model and hypothesis testing results showed that all hypotheses were supported in this study. QOL had a significant inverse association with fatigue, pruritus, and TD and a significant positive association with TA. TA partially mediated the association of QOL with fatigue, pruritus, and TD, denoting that it helped counteract the negative association of these complications on QOL. This model explained 68.5% of the total variance of QOL. Fatigue, pruritus, and TD have a negative association with QOL among patients receiving hemodialysis, while TA reduces these negative associations. Therefore, TA is greatly important to manage the associations of these complications and improve patient outcomes. Healthcare providers need to assign high priority to TA improvement among these patients to reduce their fatigue, pruritus, and TD and improve their QOL. Further studies are necessary to determine the most effective strategies for improving TA and reducing the burden of complications in this patient population.
PURPOSE: To enable departments or hospitals to mutually use medical information and eliminate the need for the burden on people and the time for the transmission of the information by reading information on a patient out of a portable storage medium and writing the medical information. CONSTITUTION: The patient submits his or her IC card 7 at the counters of departments 2-4. The IC card 7 is loaded on a terminal device to read the patient information and request information out. At the respective departments 2-4, examination results and treatment results are written as request result information on the IC card 7, which is handed over to the patient. After the patient makes a round of all the departments 2-4 to have all examinations and treatments, the patient returns to a consultation department and submits the IC card 7. At this time, the IC card 7 is loaded on a hospital information system(HIS) terminal device to read the examination results or treatment results (request result information) and store them in the HIS. Further, clinical consultation result information and dosage information are written on the IC card 7 at the consultation department.  At the accounting section, accounts information is read out of the IC card 7 to perform account settling operation, and the IC card 7 is returned to the patient.
Amino acid-based poly(ester urea)s (PEU) are emerging as a class of polymers that have shown promise in regenerative medicine applications. Embodiments of the invention relate to the synthesis of PEUs carrying pendent “clickable” groups on modified tyrosine amino acids. The pendent species include alkyne, azide, alkene, tyrosine-phenol, and ketone groups. PEUs with M w  exceeding 100k Da were obtained via interfacial polycondensation methods and the concentration of pendent groups was varied by copolymerization. The incorporation of derivatizable functionalities is demonstrated using  1 H NMR and UV-Vis spectroscopy methods. Electrospinning was used to fabricate PEU nanofibers with a diameters ranging from 350 nm to 500 nm. The nanofiber matricies possess mechanical strengths suitable for tissue engineering (Young's modulus: 300±45 MPa; tensile stress: 8.5±1.2 MPa). A series of bioactive peptides and fluorescent molecules were conjugated to the surface of the nanofibers following electrospinning using bio-orthogonal reactions in aqueous media.
The invention provides a dental composite material, a multilayer dental composite material, and a preparation method and application thereof. The preparation method of the dental composite material comprises the following steps: mixing, stirring, shearing grinding, vacuum defoaming and curing. The multi-layered dental composite is at least a 2-layered structure and comprises at least 1 layer of dental composite and/or at least 1 layer of dental polymer. The material can be layered, independent, has adjustability of structure and mechanical properties, higher fracture resistance, higher elastic modulus and longer fatigue life; the mechanical property is enhanced, and meanwhile, the characteristics of portability, attractive appearance, good biocompatibility and the like of the existing dental composite material are maintained. The preparation method comprises the following steps: stacking, dripping, calendaring and curing. The preparation method is simple to operate and low in cost, and the multi-layer dental composite material with gradient, alternating, monotone and the like can be prepared and obtained and is respectively applied to repairing molar teeth and/or premolars, incisors and/or canine teeth and caries holes at different positions.
The study is a randomized prospective unblended study. 20 male patients with ED participated to the study. Vulnerable patients, patients with a pacemaker, patients with genital lesions, previous pudendal nerve or genital surgeries, vascular disease or neurological disorders are excluded. Due to the risk of iatrogenic lesions of the erectile nerves, patients suffering from ED secondary to radical prostatectomy are not prime candidates for such a study, however due to the incidence of this etiology and the important impact in the general male population, the investigators decided to include these patients in participants study. The assessment at baseline consistes of a medical history, a neuropelveological workup of the pelvic somatic nerves, pudendal ultrasonography with doppler. Stimulation is performed using a battery powered handled stimulator (N602-1C TENS Elektrostimulator - CH). Monophasic square constant current pulse with a pulse duration of 210 μs. The patients are randomized into two separate groups, a group A with fixed stimulation at 20Hz, a group B with fixed stimulation at 60Hz. Because both genital nerves are located just few millimeters below the skin, stimulation can be achieved using two adhesive skin surface electrodes (diameter 32mm, PALS Platinum, Axelgaard, Lystrup, Denmark), one placed at the root of the penis and in vicinity of the symphysis pubis as a cathode, and a second 2-3cm lateral to the penis. Precautions are taken to ensure good contact between skin and the electrodes, including removal of hairs. Furthermore, the patients are instructed to place the electrodes correctly and to clean the skin before application of the electrodes. The patients are encouraged to set the amplitude as high as tolerable each time when stimulating at home.

Because the different genital nerves may react to different frequency of stimulation , stimulation is delivered for 30 min at the maximal tolerable stimulation amplitude at 210μs pulse width with a pulse rate at 20Hz in patients group A, and at 60Hz in patients group B.

The first transcutaneous stimulation is performed in the presence of MP: The penile tumescence and rigidity observed during stimulation are recorded in both groups of patients. Then stimulation is performed at home at least twice daily for 15 min in each session for a period of 2 weeks. The patients recorde the stimulation amplitude after each session. Erection Harness Score (EHS) and Quality of Erection Questionnaire (QEQ) are assessed for 2 weeks before stimulation, during the 2 weeks of stimulation, and for 2 weeks after the final stimulation.
Larotinib , capsules (150mg\*2+50mg\*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to 26, participants received rifampin 600 mg as capsules, orally, once daily (QD) and Larotinib 350 mg as capsules, orally was coadministered on Day 20. There was a washout period of 13 days between the two treatments.
This study evaluates a combined economic empowerment and child rights intervention to prevent violence against children and exploitation of children in ultra-poor communities in Burkina Faso. This evaluation study takes place in the Nord Region of Burkina Faso which is located in the Sahel Desert on the border to Mali. The Nord Region is characterized by extreme poverty and an ongoing food and nutrition crisis due to cyclical droughts. Extreme poverty heightens risks of violence and exploitation of children, particularly girls, who may end up in the worst forms of child labor as defined by the UN (e.g., slavery, debt bondage, forced or hazardous work in gold mines, cotton fields, or plantations in the Ivory Coast or in the South of Burkina Faso, involving physical deprivation and violence). About 1.25 million (or 37.8%) of children ages 5-14 in Burkina Faso are working to augment the incomes of their families, or because their families are too poor to support them. Adolescent girls being sent away to work as maids, facing risks of sexual exploitation and abuse. Boys being sent to religious schools madrassas, where they are made to do unpaid and/or hazardous work including begging in the street, and are subject to physical abuse.

The study employs a 3-arm cluster (group) randomized control trial design with baseline and one-year follow-up and includes 360 households (120 households per arm). Each selected household includes a female primary caregiver with a child between the ages of 10-15 who is also able to participate in the evaluation study. The study evaluates the efficacy of an economic empowerment program (Trickle Up) and a combination economic empowerment and child rights sensitization program (Trickle Up Plus) to prevent child separation and potential subsequent exposure to exploitation, abuse, and hazardous working conditions among children. Randomization occurred at the village level to assign households to three study arms: Trickle Up, Trickle Up Plus or the wait-list condition which serves as the control arm. Participants were recruited from 12 impoverished comparable villages that were selected based on socio-economic status (poverty ranking and food insecurity), geography, population size, and distance from urban center. Within these communities, families living in ultra-poverty were identified using a Participatory Wealth Ranking (PWR) exercise.

The evaluation study is implemented in partnership with the Trickle Up organization, Women's Refugee Council (WRC), and Aide aux Enfants et aux Families Démunies (ADEFAD).
PURPOSE: To obtain a makeup cosmetic for legs improving the beauty of leg lines and having excellent rubbing resistance to cloths and moisture retentive effect. CONSTITUTION: This makeup cosmetic for legs is composed of the first agent containing powder and occasionally further a cosmetic additive and the second agent containing a coating film-forming material for forming a film on the leg part and a volatile solvent (preferably ethanol). The first agent is coated on the leg part and then, the second agent is coated. The film-forming material is selected from the group consisting of an acrylic resin, a vinyl-based resin, an acrylic- and a vinyl-based copolymer, a condensation-based resin, a natural resin, a silicone resin and a cellulosic resin, especially the first three are preferable, especially the resin having betaine acetate group expressed by formula I (n is 1-18) in the molecule, e.g. an acrylic resin expressed by formula II ((n+m) is 400-450; R is 1-18C alkyl) is preferable.  The second agent is preferably contains the film-forming material in an amount of 0.1-30wt.% and a volatile solvent in an amount of 50-99.9wt.%.
* Instruct patients and caregivers that CREON should only be taken as directed by their healthcare professional. Patients should be advised that the total daily dose should not exceed 10,000 lipase units/kg body weight/day unless clinically indicated. This needs to be especially emphasized for patients eating multiple snacks and meals per day. Patients should be informed that if a dose is missed, the next dose should be taken with the next meal or snack as directed. Doses should not be doubled . [see Dosage and Administration ( )] 2
  * Instruct patients and caregivers that CREON should always be taken with food. Patients should be advised that CREON delayed-release capsules and the capsule contents must not be crushed or chewed as doing so could cause early release of enzymes and/or loss of enzymatic activity. Patients should swallow the intact capsules with adequate amounts of liquid at mealtimes. If necessary, the capsule contents can also be sprinkled on soft acidic foods . [see Dosage and Administration ( )] 2
PURPOSE:To obtain the composition for disinfecting the hands and the fingers which has a sufficient bactericidal power, is of a fast drying type and hardly causes skin injuries even in the case of high using frequencies by selecting an emollient agent from a group consisting of diester of dibasic acid, triester of citric acid and triester of phosphoric acid. CONSTITUTION:The composition for disinfecting the hands and the fingers is the composition for disinfecting the hands and the fingers contg. ethanol for disinfection, the bactericide and the emollient agent. The bactericide is at least one kind selected from a group consisting of chlorohexydine gluoconate, alkylpyridinum salt and quaternary ammonium salt and the emollient agent is at least one kind selected from the group consisting of the dieser of dibasic acid, triester of citric acid, and triester of phosphoric acid. All the emollient agents act as a softening agent and sebum component replenishing agent of the skin and suppresses the skin injuries, such as skin irritation and skin roughening by the ethanol component. The emollient agent has simultaneously the effect of intensifying the bactericidal power of the bactericide incorporated into the compsn. The intensification of the bactericidal power is conceivably resulted from the intensification of the effect of the bactericide of the bacterial cells by the cooperative effect of the emollient agent and the bactericide.
Patients undergo radiation therapy and receive cisplatin or carboplatin on day 1 of each cycle and etoposide on days 1-3 for 4 cycles. Patients then receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan during screening. Patients also undergo MRI throughout the trial as well as CT. Additionally, patients undergo blood sample collection throughout the trial.
BACKGROUND: This study's purposes were to evaluate the impact of biological therapies on outcomes in patients with severe asthma (SA) and chronic rhinosinusitis (CRS) and to compare these effects among those with NP (CRSwNP) versus those without NP (CRSsNP) in the "real-world" setting in Saudi Arabian patients.
METHODS: From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital-Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of dupilumab therapy. Outcomes were assessed, including clinical outcomes, FEV1, and laboratory findings before and one year after dupilumab. Post-therapy effects were compared between CRSwNP and CRSsNP.
RESULTS: Fifty subjects were enrolled, with a mean age of 46.56. There were 27 (54%) females and 23(46%) males. Significant improvements in clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory ones (serum IgE and eosinophilic count) were observed 6 and 12 months after using dupilumab (p < 0.001), respectively. However, after 12 months of dupilumab therapy, there were no significant differences between those with and without NP with regards to clinical (anosmia, ACT, and OCs use), laboratory (eosinophilic count, serum IgE level) parameters, and FEV1%.
CONCLUSIONS: Patients with CRS experienced significant improvements in clinical, FEV1, and laboratory outcomes after dupilumab therapy. However, these improvements were not maintained when comparing CRSwNP with CRSsNP. There were no significant differences between those with and without NP regarding ACT and OCs use or laboratory (eosinophilic count, serum IgE level) parameters. Further prospective multicenter studies are warranted.
Health care information system that stores information on referee medical institutions that are of relatively large size or otherwise having high-level expertise in specific diagnostic care and diseases, and based on information input by doctors at clinics or relatively small hospitals, selects appropriate referee medical institutions. Assistance is provided when the referrer medical institution sends a referral letter; and assistance is also provided when the referee hospital sends back patient examination reports. Information on hospitals ( 11 ), ( 12 ), . . . among referee medical institutions ( 1 ) is stored in a referee hospital information database ( 211 ) at a health care information center ( 2 ). Based on patient referral information from a referrer medical institution ( 3 ), an appropriate referee medical institution is selected, and information on the selected institution is presented to the referrer medical institution ( 3 ).
The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).